Table 1. Clinical and molecular characteristics of the development (Stanford) and validation (TCGA) cohorts.

Clinical data for the validation cohort were available on 114 subjects, and molecular data were available on 107 subjects (missing data are noted). KPS is shown as three categories and a mean value. Tumor location, EGFR amplification, IDH1 mutation, and MGMT promoter hypermethylation are tabulated as number (n) and percentage.

CharacteristicStanford
development
cohort
(n = 121)
TCGA
validation
cohort
(n = 144)
Age, mean (SD)64.6 (14.1)58.5 (15.1)
Sex, n male (%)69 (57)73 (64)
KPS, n (%)
  >70%65 (54)78 (68)
  50–70%44 (37)19 (17)
  <50%11 (9)1 (1)
  Missing116
  Mean ± SD71.7 ± 1778.6 ± 12.3
Location, n (%)
  Frontal42 (35)
  Parietal23 (19)
  Basal ganglia3 (3)
  Temporal49 (41)
  Occipital4 (3)
EGFR amplification, n (%)21 (17)100 (69)
  Missing7426
IDH1 mutation, n (%)4 (4)
  Missing22
MGMT hypermethylation, n (%)27 (22)25 (23)
  Missing7360
Molecular subgroups, n (%)
  Proneural32 (30)
  Neural18 (17)
  Mesenchymal31 (29)
  Classical25 (23)
  Missing1